Kent Academic Repository

Full text document (pdf)

Citation for published version

Sakhnevych, Svetlana S. and Yasinska, Inna M. and Bratt, Alison M. and Benlaouer, Ouafa and Gonçalves Silva, Isabel and Hussain, Rohanah and Siligardi, Giuliano and Fiedler, Walter and Wellbrock, Jasmin and Gibbs, Bernhard F. and Ushkaryov, Yuri A. and Sumbayev, Vadim V. (2018) Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing

DOI

https://doi.org/10.1038/s41423-018-0053-8

Link to record in KAR

http://kar.kent.ac.uk/68463/

Document Version

Author's Accepted Manuscript

Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

Versions of research
The version in the Kent Academic Repository may differ from the final published version.
Users are advised to check **http://kar.kent.ac.uk** for the status of the paper. **Users should always cite the published version of record.**

Enquiries
For any further enquiries regarding the licence status of this document, please contact:
researchsupport@kent.ac.uk

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at **http://kar.kent.ac.uk/contact.html**

KAR Kent Academic Repository

University of Kent

1 **Cortisol facilitates immune escape of human acute myeloid leukaemia cells by inducing**
2 **latrophilin 1 expression**

3

4 Svetlana S. Sakhnevych[a], Inna M. Yasinska[a], Alison M. Bratt[a], Ouafa Benlaouer[a], Isabel
5 Gonçalves Silva[a], Rohanah Hussain[b], Giuliano Siligardi[b], Walter Fiedler[c], Jasmin Wellbrock[c],
6 Bernhard F. Gibbs[a,d], Yuri A. Ushkaryov[a], Vadim V. Sumbayev[a,*]

7

8 [a] School of Pharmacy, University of Kent, Chatham Maritime, United Kingdom
9 [b] Beamline B23, Diamond Light Source, Didcot, UK
10 [c] Department of Oncology, Hematology and Bone Marrow Transplantation with Section
11 Pneumology, Hubertus Wald University Cancer Center, University Medical Center
12 Hamburg-Eppendorf, Germany
13 [d] Department of Medicine, Dermatology and Allergology, University of Oldenburg, Germany

14

15 [*] **Corresponding author**
16 E-mail addresses: V.Sumbayev@kent.ac.uk

17

18

19

20

21

22

Progression of acute myeloid leukaemia (AML) – the most severe blood/bone marrow cancer – is determined by the ability of malignant cells to escape host immune surveillance. However, the systemic regulation mechanisms underlying this phenomenon remain largely unknown. In this study we have discovered a fundamental systemic biochemical strategy which allows AML cells to employ physiological body systems to survive and escape immune attack. We found that AML cells use a crucial human adrenal cortex hormone (cortisol) to induce the expression of the neuronal receptor latrophilin 1 (LPHN1) which facilitates exocytosis. This receptor interacts with the blood plasma protein FLRT3 (fibronectin leucine rich transmembrane protein 3) to cause secretion of the immune suppressor galectin-9 which impairs the anti-cancer activities of cytotoxic lymphoid cells.

AML is a cancer of the blood and bone marrow which originates from self-renewing malignant immature myeloid cells and rapidly becomes a systemic, and very often fatal, malignancy[1]. AML cells employ body systems to produce factors required for their proliferation/disease progression[2,3]. This includes employment of stem cell factor (SCF), a major hematopoietic growth factor controlling AML progression and thus becoming highly oncogenic[2,3]. Expression and release of SCF can be triggered by AML cells via cytokines (e.g. interleukin-1β)[2]. Recent evidence clearly demonstrated that AML cells are also capable of impairing the activities of cytotoxic lymphoid cells (e.g. natural killer (NK) cells and cytotoxic T cells[4]). One of the biochemical mechanisms underlying this phenomenon lies in the ability of AML cells to secrete the protein called galectin-9. This tandem type galectin binds the immune receptor Tim-3 and induces a variety of intracellular and cell-to-cell signalling events leading to the inactivation of NK cells as well as killing of cytotoxic T cells[4,5]. We recently reported that the process of galectin-9 secretion in AML cells is stimulated by the unique G protein-coupled receptor LPHN1, which normally functions in neurons facilitating exocytosis[4,6]. LPHN1 is also found in haematopoietic stem cells (HSCs)

48 but its expression disappears at early stages of their maturation[4,7]. However, upon malignant
49 transformation, AML cells preserve their abilities to express LPHN1 and produce high levels
50 of galectin-9 and Tim-3, where the latter is involved in trafficking galectin-9 during the
51 secretion process (HSCs express neither galectin-9 nor Tim-3[4]).

52 It is currently unknown which molecular mechanisms trigger high levels of LPHN1
53 expression in primary human AML cells, and in general mechanisms of upregulation of
54 LPHN1 expression at the genomic level remain unclear. It is also unknown whether FLRT3,
55 a natural LPHN1 ligand[4,8], is present in human blood plasma and other tissues associated
56 with AML. Unravelling these mechanisms is crucial in order to understand the pathways that
57 control the ability of AML cells to protect themselves against cytotoxic lymphoid cells and
58 thus was the aim of the present study.

59 **Results and Discussion**

60 In order to investigate the effects of cortisol on LPHN1 transcription, we exposed primary
61 and THP-1 human AML cells, primary human HSCs and primary healthy human leukocytes
62 to 1 μM cortisol for 24 h followed by quantitative real-time PCR analysis of LPHN1 mRNA
63 levels. We found that all cell types, except primary healthy leukocytes, transcribed detectable
64 amounts of LPHN1 mRNA and in all these cases levels were significantly upregulated by
65 treatment with cortisol (Figure 1A). In both THP-1 and primary human AML cells LPHN1
66 protein levels were also clearly upregulated (Figure 1B and C). In contrast, primary human
67 healthy leukocytes did not express detectable amounts of LPHN1 protein and this was not
68 altered by the effects of cortisol (Figure 1D). Comparative analysis of LPHN1 protein
69 expression in primary human AML cells, THP-1 cells and primary human healthy leukocytes
70 is shown in Supplementary figure 1.

71 Cortisol treatments did not upregulate galectin-9 secretion in any of these cell types (Figure 1
72 B-D), suggesting that LPHN1 needs to be activated by a ligand to induce galectin-9 release.

73 Analysis of blood plasma levels of cortisol in AML patients vs healthy donors (samples were
74 collected at the same time of the day to avoid the influence of circadian dynamics)
75 demonstrated that its levels were significantly higher in the blood plasma of AML patients
76 compared to healthy donors (Figure 1E). Galectin-9 levels were also substantially higher in
77 AML patients (Figure 1F), which is in line with our previous observations[4]. Furthermore,
78 there was no correlation between cortisol and galectin-9 levels in the blood plasma of healthy
79 donors, while in AML patients there was a clear correlation (Figure 1G), suggesting that
80 galectin-9 secretion in this case might be linked to LPHN1 expression.

81 If LPHN1 is expressed on the surface of blood cells, it can also be shed by proteolysis and
82 therefore appear in the plasma. LPHN1 was immunoprecipitated, extracted and subjected to
83 Western blot analysis from blood plasma samples from AML patients using several LPHN1
84 antibodies. A clear fragment was detectable at around 67-68 kDa, smaller fragments were
85 detectable as well, but only in AML plasma, while in the blood plasma of healthy donors
86 there was no evidence of the presence of LPHN1 fragments (Figure 1H). These fragments
87 were also detectable by ELISA (Figure 1I, see Materials and Methods for description of the
88 ELISA format).

89 As reported before[4], we observed that exposure of THP-1 AML cells to 10 nM FLRT3 for 16
90 h resulted in a significant increase in galectin-9 secretion (Figure 2A). This effect was not
91 detectable in primary healthy human leukocytes (Figure 2A). Importantly, 1 h pre-exposure
92 of THP-1 cells to rabbit polyclonal antibody recognising LPHN1 (clone name RL1[9]) prior to
93 16 h treatment with 10 nM FLRT3 attenuated FLRT3-induced galectin-9 release, confirming
94 involvement of LPHN1 in this process (Figure 2A). The antibody employed specifically

95 recognised target molecules on the surface of THP-1 cells (Supplementary figure 2). We used
96 mouse neuroblastoma cells NB2A, which do not express LPHN1[10], as a negative control and
97 measured the interaction of the antibody with the cell surface using a Li-Cor on-cell assay as
98 described in the Materials and Methods (please see supplementary information). Exposure of
99 THP-1 cells to 1 μg/ml RL1 for 16 h did not affect galectin-9 secretion levels (data not
100 shown) suggesting that this antibody lacks a LPHN1 agonistic effect.

101 Interestingly, we found that blood plasma of both healthy donors and AML patients contains
102 approximately equal amounts of secreted FLRT3 (most likely by proteolytic shedding) with a
103 molecular weight of approximately 55 kDa (which corresponds to the molecular weight of
104 FLRT3 shed from the cell surface by proteinases[11]). Another specific band was seen at
105 around 27-28 kDa which most likely corresponds to a smaller cleavage fragment of the
106 FLRT3 extracellular domain (Figure 2B). The amounts of this smaller fragment were also
107 equal in blood plasma of healthy donors and AML patients (Figure 2B). To explore which
108 blood plasma-based ligands can induce galectin-9 secretion in AML cells we cultured THP-1
109 cells in RPMI-1640 medium containing antibiotics (as outlined in Materials and Methods –
110 see supplementary information) replacing 10 % foetal bovine serum (FBS) with blood plasma
111 from either healthy donors or AML patients. Cells were incubated for 16 h with or without 30
112 min pre-incubation with anti-FLRT3 antibody in order to neutralise FLRT3 activity.
113 Galectin-9 secretion levels were significantly higher in the presence of both sources of human
114 blood plasma compared to FBS (negative control). Anti-FLRT3 antibody attenuated galectin-
115 9 secretion (Figure 2C). Binding of LPHN1 and FLRT3 was further confirmed using SRCD
116 spectroscopy. We found that the two proteins interact with each other with high affinity,
117 inducing conformational change in both proteins, as seen from far UV synchrotron radiation
118 circular dichroism (SRCD) spectra (Figure 2D). This is further confirmation of the high

119 affinity interaction of LPHN1 and FLRT3 observed in previous studies[8] using different
120 techniques.

121 Taken together, our results demonstrate, for the first time, that cortisol upregulates LPHN1
122 expression at the transcriptional level, thus stimulating its translation in human AML cells.
123 AML leads to a decreased blood plasma glucose levels[5], which normally leads to
124 upregulation of secretion of corticotropin-releasing hormone (CTRH) by hypothalamus[12].
125 CTRH induces secretion of adrenocorticotropic hormone (ACTH) by pituitary gland[12].
126 ACTH upregulates cortisol production by the adrenal cortex[12]. Cortisol is then employed by
127 AML cells. In healthy human leukocytes cortisol is not capable of inducing LPHN1
128 transcription/translation, possibly because of gene repression. Interaction of AML cell-
129 derived LPHN1 with released FLRT3 available in blood plasma facilitates the secretion of
130 galectin-9. The latter protects AML cells against immune attack which could otherwise be
131 performed by NK cells as well as cytotoxic T cells (Supplementary figure 3). Importantly,
132 LPHN1 fragments are present in the blood plasma of AML patients but not in healthy donors.
133 These fragments were detectable by both Western blot analysis and ELISA, which indicates
134 the possibility of detection of these fragments for rapid AML diagnosis, although differential
135 verification tests have yet to be performed. Our results suggest a fundamentally novel
136 mechanism used by AML cells in order to progress the disease. They use a common
137 endogenous human hormone (cortisol) to induce LPHN1 expression by employing a widely
138 available ligand (FLRT3, which is always present in blood plasma) in order to escape host
139 immune surveillance. Thus, AML cells employ crucial functional systems of the human body
140 to support their survival and attenuate the anti-cancer activities of cytotoxic lymphoid cells.
141 Our work indicates that galectin-9 and secreted FLRT3 are the most promising targets for
142 anti-AML immune therapy.

143

144

145 **Materials and Methods are presented in Supplementary Information.**

146

147 **Acknowledgements**

148 This work was supported by a Daphne Jackson Trust postdoctoral fellowship (to IMY),
149 University of Kent Faculty of Sciences Research Fund (to VVS). We thank Diamond Light
150 Source for access to B23 beamline (SM12578).

151

152 **Conflict of interest**

153

154 The Authors have no conflict of interest to declare

155

156

157

158

159

160

161

162

163

164

165

166

167

168 **References**

169 1. Estey E, Döhner, H. Acute Myeloid Leukaemia. Lancet 2006, **368:** 1894–907.
170 2. Wyszynski RW, Gibbs BF, Varani L, Iannotta D, Sumbayev VV. Interleukin-1 beta
171 induces the expression and production of stem cell factor by epithelial cells: crucial
172 involvement of the PI-3K/mTOR pathway and HIF-1 transcription complex. Cell Mol
173 Immunol 2016, **13**: 47-56.
174 3. Yasinska IM, Gonzalves Silva I, Sakhnevych SS, Ruegg L, Hussain R, Siligardi G, et
175 al. High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute
176 myeloid leukaemia progression. OncoImmunology 2018, **7**: e1438109
177 4. Goncalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M,
178 et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of
179 Human Acute Myeloid Leukemia Cells. EBioMedicine 2017, **22:** 44-57.
180 5. Goncalves Silva I, Ruegg L, Gibbs BF, Bardelli M, Fruehwirth A, Varani L, et al. The
181 immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in
182 human myeloid leukemia cells. OncoImmunology 2016, **5:** e1195535.
183 6. Sumbayev VV, Goncalves Silva I, Blackburn J, Gibbs BF, Yasinska IM, Garrett MD,
184 et al. Expression of functional neuronal receptor latrophilin 1 in human acute myeloid
185 leukaemia cells. Oncotarget 2016, **7:** 45575-45583.
186 7. Maiga A. Lemieux S, Pabst C, Lavallee VP, Bouvier M, Sauvageau G, and Hebert J.
187 Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups
188 of acute myeloid leukemia: identification of potential disease-specific targets. Blood
189 Cancer J. 2016, **6**: e431.

190 8. Boucard AA, Maxeiner S, Sudhof TC. Latrophilins function as heterophilic cell-
191 adhesion molecules by binding to teneurins: regulation by alternative splicing. J. Biol.
192 Chem. 2014, **289**: 387-402.
193 9. Volynski, KE, Meunier FA, Lelianova VG, et al. Latrophilin, neurexin, and their
194 signaling-deficient mutants facilitate α-latrotoxin insertion into membranes but are not
195 involved in pore formation. J Biol Chem 2000, **275:** 41175-41183.
196 10. Silva JP, Lelianova VG, Ermolyuk YS, et al. Latrophilin 1 and its endogenous ligand
197 Lasso/teneurin-2 form a high-affinity transsynaptic receptor pair with signaling
198 capabilities. Proc. Natl. Acad. Sci. U. S. A. 2011, **108:** 12113-12118.
199 11. Yamaguchi S, Hampel F, Hata K. et al. FLRT2 and FLRT3 act as repulsive guidance
200 cues for Unc5-positive neurons. EMBO J. 2011, **30:** 2920-2933.
201 12. Tabata I, Ogita F, Miyachi M, Shibayama H. Effect of low blood glucose on plasma
202 CRF, ACTH, and cortisol during prolonged physical exercise. J Appl Physiol. 1991,
203 **71**: 1807-181.
204
205
206
207
208
209
210
211

Figure legends.

Figure 1. Cortisol induces LPHN1 expression in human AML cells and haematopoietic stem cells but not in primary healthy human leukocytes. Primary human AML, THP-1 and haematopoietic stem cells as well as primary healthy leukocytes were exposed to 1 μM cortisol for 24 h followed by analysis of LPHN1 gene transcription by quantitative real-time PCR (A) and Western blot analysis (B – primary AML cells, C – THP-1 cells and D – PHL). For PHL, lysates of LPHN1 overexpressing NB2A cells were used as a positive control. ELISA was used to measure secreted galectin-9 levels. Blood plasma of ten healthy donors and ten AML patients was collected at the same time of the day to ensure comparability of cortisol levels. Cortisol (E) and galectin-9 (F) levels were measured by ELISA and correlation between the levels of these two proteins was analysed (G). Soluble LPHN1 fragments were immunoprecipitated and detected by Western blot (H) and ELISA (I), as outlined in Materials and Methods. Images are from one experiment representative of four – six which gave similar results. Data represent mean values ± SEM of six – ten independent experiments. ; $*p < 0.05$; $**p < 0.01$; $***p < 0.01$ vs. control.

Figure 2. FLRT3 induces galectin-9 secretion in AML cells in a LPHN1-dependent manner. THP-1 cells and PHL were exposed to 10 nM human recombinant FLRT3 for 16 h, followed by detection of secreted galectin-9 by ELISA. In THP-1 cells, the treatment was performed with or without 1 h pre-exposure to 1 μg/ml RL1 anti-LPHN1 polyclonal antibody

235 (A). The levels of released FLRT3 fragments were analysed in the blood plasma of healthy
236 donors and AML patients using Western blot (B). THP-1 cells were exposed for 16 h to 10%
237 blood plasma either from healthy donors or AML patients, with or without pre-treatment with
238 FLRT3 neutralising antibody. Levels of secreted galectin-9 were analysed using ELISA. (C).
239 Secondary structure and conformational changes of LPHN1, FLRT3 and the complex of the
240 two proteins were characterised using SRCD spectroscopy as outlined in Materials and
241 Methods (D). Images are shown from one representative experiment of four which gave
242 similar results. Data are shown as mean values ± SEM from four independent experiments;
243 *p < 0.05; **p < 0.01 vs. control.

244

245 **Figure 1**



246

247 **Figure 2**



248

249

250

251 **Supplementary Information**

252 **Cortisol facilitates immune escape of human acute myeloid leukaemia cells by inducing**

253 **latrophilin 1 expression**

254

255 Svetlana S. Sakhnevych[a], Inna M. Yasinska[a], Alison M. Bratt[a], Ouafa Benlaouer[a], Isabel

256 Gonçalves Silva[a], Rohanah Hussain[b], Giuliano Siligardi[b], Walter Fiedler[c], Jasmin Wellbrock[c],

257 Bernhard F. Gibbs[a,d], Yuri A. Ushkaryov[a], Vadim V. Sumbayev[a,*]

258

259 [a] School of Pharmacy, University of Kent, Chatham Maritime, United Kingdom

260 [b] Beamline B23, Diamond Light Source, Didcot, UK

261 [c] Department of Oncology, Hematology and Bone Marrow Transplantation with Section
262 Pneumology, Hubertus Wald University Cancer Center, University Medical Center
263 Hamburg-Eppendorf, Germany
264 [d] Department of Medicine, Dermatology and Allergology, University of Oldenburg, Germany
265
266 [*] **Corresponding author**
267 E-mail addresses: V.Sumbayev@kent.ac.uk
268
269
270
271
272
273
274
275
276 **Materials and Methods**
277
278 **Materials**
279 RPMI-1640 medium, foetal bovine serum, supplements as well as basic laboratory chemicals
280 were purchased from Sigma-Aldrich (Suffolk, UK). Maxisorp™ microtitre plates were
281 obtained from Nunc (Roskilde, Denmark) and Oxley Hughes Ltd (London, UK). Human
282 recombinant FLRT3, mouse monoclonal antibody against LPHN1 and rabbit antibody against
283 FLRT3 were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). PAL1 and
284 RL1 rabbit polyclonal antibodies against LPHN1 were described previously[1,2]. Rabbit
285 antibody against native LPHN1 was obtained from Abcam (Cambridge, UK). Goat anti-
286 mouse and goat anti-rabbit fluorescence dye-labelled antibodies were obtained from LI-COR

287 (Lincoln, Nebraska USA). ELISA-based assay kits for the detection of galectin-9 were
288 purchased from Bio-Techne (R&D Systems, Abingdon, UK). A soluble extracellular
289 fragment of LPHN1, LPH-51, was produced and purified as described before[2]. Briefly, NB2a
290 cells stably expressing LPH-51 were cultured in serum-free medium for 48 h. 30 mL of the
291 medium was then incubated overnight at 4°C with 500 μL of anti-V5-antibody agarose
292 (Sigma-Aldrich). After incubation, the column was washed with 10 column volumes of PBS.
293 Bound protein was fractionally eluted with 5 volumes of elution buffer containing 50 mM
294 triethylamine and 150 mM NaCl (pH 12). The eluted protein was immediately neutralized
295 with 150 mM NaCl, 1 M HEPES (pH 7.2)[9]. The fractions were then analysed by Western
296 blotting and combined. The protein was concentrated using Amicon centrifugal ultrafiltration
297 units with a 30,000 molecular weight cut-off (Sigma-Aldrich). All other chemicals purchased
298 were of the highest grade of purity commercially available.

299

300

301 **Cell lines and primary cells**

302 THP-1 human myeloid leukemia monocytes cells were obtained from the European
303 Collection of Cell Cultures (Salisbury, UK). Cells were cultured in RPMI 1640 medium
304 (R8758 – Sigma-Aldrich) with L-glutamine and sodium bicarbonate, liquid, sterile-filtered,
305 suitable for cell culture) supplemented with 10% foetal bovine serum, penicillin (50 IU/ml)
306 and streptomycin sulphate (50 μg/ml). Untransfected mouse neuroblastoma cells (NB2A) and
307 those overexpressing the full-size LPHN1 (LPH-42) were handled as described earlier[9].

308 Primary human AML cells were obtained from the sample bank of the University Medical
309 Centre Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer Hamburg, reference:

310 PV3469). Cells were incubated in IMDM medium containing 15% BIT 9500 serum
311 substitute, 100 μM mercaptoethanol, 100 ng/ml stem cell factor (SCF), 50 ng/ml FLT3, 20
312 ng/ml G-CSF, 20 ng/ml IL-3, 1 μM UM729 and 500 nM stemregenin 1 (SR1) as described
313 before[3].

314 **Primary human blood plasma samples**

315 Blood plasma from healthy donors was generated by centrifugation of peripheral blood
316 provided by the National Health Blood and Transfusion Service (NHSBT, UK) following
317 ethical approval (REC reference: 16-SS-033). Primary human AML plasma samples were
318 obtained from the sample bank of University Medical Centre Hamburg-Eppendorf (Ethik-
319 Kommission der Ärztekammer Hamburg, reference: PV3469)[4].

320 **Western blot analysis**

321 LPHN1 protein levels were analysed using Western blotting. β-actin staining was used to
322 confirm equal protein loading as described previously (4, 6, 14). LI-COR goat secondary
323 antibodies (dilution 1:2000), conjugated with fluorescent dyes, were used in accordance with
324 manufacturer's protocol to visualise target proteins (using a LI-COR Odyssey imaging
325 system). Western blot data were quantitatively analysed using Odyssey software and values
326 were subsequently normalised against those of β-actin[1,4,5].

327 **Enzyme-linked immunosorbent assays (ELISAs) and immunoprecipitation**

328 Secreted galectin-9 was measured by ELISA using R&D Systems kits according to
329 manufacturer's protocol. Plasma cortisol was measured by ELISA using the Salimetrics assay
330 kit according to the manufacturer's protocols (Salimetrics, Suffolk, UK.)

331 For immunoprecipitation of LPHN1 fragments from human blood plasma, plates were coated
332 with mouse monoclonal LPHN1 antibody following the principle and protocol described

333 previously[5]. This was followed by blocking with 2% BSA. Samples were then applied and
334 incubated for at least 4 h at room temperature after which plates were extensively washed
335 with Tris buffered saline with Tween-20 (TBST). Glycine-HCl pH lowering buffer (pH 2.0)
336 was then applied to extract the bound proteins. Extracts were mixed with equal volumes of
337 lysis buffer (pH 7.5) and with 4× sample buffer for SDS-PAGE at a ratio of 1:3. Samples
338 were then subjected to Western blot analysis (5), using rabbit PAL1 anti-LPHN1 antibody.
339 Alternatively, PAL1 antibody was applied as detection antibody, followed by visualisation
340 using HRP-labelled anti-rabbit secondary antibody (Abcam, Cambridge, UK).

341 **On cell assays**

342 We employed a standard LI-COR on cell assay to characterise interaction of RL-1 antibody
343 with the surface of THP-1 cells[4,5].

344

345

346 **Synchrotron radiation circular dichroism (SRCD) spectroscopy**

347 Human recombinant LPHN1 and FLRT3 were analysed, either alone or in combination with
348 each other, using SRCD spectroscopy at beamline B23, Diamond Light Source (Didcot, UK).
349 (The B23 is equipped with a highly collimated microbeam allowing the use of small aperture
350 long path length microcuvettes[6-9]). SRCD measurements were carried out using 0.01 µM
351 sample of soluble LPH-51 in a 1 cm path length cell of 3 mm aperture diameter using a
352 Module B instrument with 1 nm increment, 1 s integration time and 1.2 nm bandwidth at 23
353 °C. The cuvette capacity was 60 µl. Titration experiments were conducted as described
354 previously[3] using standard far-UV measurements.

355 **Statistical analysis**

Each experiment was performed at least three times and statistical analysis was conducted using a two-tailed Student's t-test, where appropriate. Multiple comparisons were performed using an ANOVA test. Post-hoc Bonferroni correction was applied. Statistical probabilities (p) were expressed as * where $p<0.05$; **, $p<0.01$ and *** when $p<0.001$. Coefficient of determination (R^2) was calculated using GraphPad Prism software in order to assess correlation.

References

1. Sumbayev VV, Goncalves Silva I, Blackburn J, Gibbs BF, Yasinska IM, Garrett MD, et al. Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells. Oncotarget 2016, **7:** 45575-45583.
2. Volynski, KE, Meunier FA, Lelianova VG, et al. Latrophilin, neurexin, and their signaling-deficient mutants facilitate α-latrotoxin insertion into membranes but are not involved in pore formation. J Biol Chem 2000, **275:** 41175-41183.

376 3. Yasinska, I.M., Ceccone, G., Ojea-Jimenes, I., et al. (2018) Highly specific targeting
377 of human acute myeloid leukaemia cells using pharmacologically active
378 nanoconjugates. Nanoscale. 10: 5827
379 4. Goncalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M,
380 et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of
381 Human Acute Myeloid Leukemia Cells. EBioMedicine 2017, **22:** 44-57.
382 5. Silva, J.P., Lelianova, V.G., Ermolyuk, Y.S., et al. (2011) Latrophilin 1 and its
383 endogenous ligand Lasso/teneurin-2 form a high-affinity transsynaptic receptor pair
384 with signaling capabilities. Proc. Natl. Acad. Sci. U. S. A. 108, 12113-12118.
385 6. Hussain, R., Javorfi, T., and Siligardi, G. (2012) Circular dichroism beamline B23 at
386 the Diamond Light Source. J. Synchrotron Radiat. 19, 132-135.
387 7. Hussain, R., Jávorfi, T. and Siligardi, G. (2012) Spectroscopic Analysis: Synchrotron
388 Radiation Circular Dichroism. Comprehensive Chiral. 8, 438-448.
389 8. Hussain, R., Benning, K., Myatt, D., Javorfi, T., Longo, E., Rudd, T.R., Pulford, B.,
390 and Siligardi, G. (2015) CDApps: integrated software for experimental planning and
391 data processing at beamline B23, Diamond Light Source. J. Synchrotron Radiat. 22,
392 862.
393 9. Hill, V. (1910) The possible effects of the aggregation of the molecules of
394 hæmoglobin on its dissociation curves, J Physiol. 40: iv–vii.

395

396

397 **Supplementary Figures**

398

399 **Cortisol facilitates immune escape of human acute myeloid leukaemia cells by inducing**
400 **latrophilin 1 expression**

401

402 Svetlana S. Sakhnevych[a], Inna M. Yasinska[a], Alison M. Bratt[a], Ouafa Benlaouer[a], Isabel

403 Gonçalves Silva[a], Rohanah Hussain[b], Giuliano Siligardi[b], Walter Fiedler[c], Jasmin Wellbrock[c],

404 Bernhard F. Gibbs[a,d], Yuri A. Ushkaryov[a], Vadim V. Sumbayev[a,*]

405 [a] School of Pharmacy, University of Kent, Chatham Maritime, United Kingdom

406 [b] Beamline B23, Diamond Light Source, Didcot, UK

407 [c] Department of Oncology, Hematology and Bone Marrow Transplantation with Section

408 Pneumology, Hubertus Wald University Cancer Center, University Medical Center

409 Hamburg-Eppendorf, Germany

410 [d] Department of Medicine, Dermatology and Allergology, University of Oldenburg, Germany

411

412



413

414

415 **Supplementary figure 1. Comparative analysis of LPHN1 protein expression in primary**
416 **human AML, THP-1 cells and PHL.** Lysates of each cell type were subjected to Western
417 blot analysis as outlined in the Materials and Methods. Images are from one experiment
418 representative of three which gave similar results. Data represent mean values ± SEM of
419 three independent experiments; **$p < 0.01$ vs. AML cells.

420

421

422

423

424

425

426

427



428

429

430 **Supplementary figure 2. Cell surface detection of LPHN1.** Wild type NB2A cells
431 (negative control) and THP-1 cells were subjected to an on-cell assay using anti-rabbit Li-Cor
432 secondary antibody. Images are from one experiment representative of three which gave
433 similar results.

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451



452

453

454 **Supplementary figure 3. Physiological cross-links leading to cortisol-induced**
455 **upregulation of LPHN1 expression in AML cells followed by facilitation of galectin-9**
456 **secretion in a FLRT3-dependent manner.** AML is associated with a decreased blood
457 plasma glucose levels, which normally leads to upregulation of secretion of corticotropin-
458 releasing hormone (CTRH) by hypothalamus. CTRH induces secretion of adrenocorticotropic
459 hormone (ACTH) by pituitary gland. Secreted ACTH upregulates cortisol production by the
460 adrenal cortex, thus leading to cortisol-induced upregulation of LPHN1 levels in AML cells.

461 Galectin-9, secreted in FLRT3-LPHN1-dependent manner attenuates anti-cancer activity of
462 cytotoxic T cells (CTC) and NK cells.

463

464

465

466